Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States

BACKGROUND: Vorapaxar is a protease‐activated receptor‐1 antagonist approved by the U.S. Food and Drug Administration (FDA) for the reduction of thrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) and peripheral artery disease (PAD), without a previous stro...

Descripción completa

Detalles Bibliográficos
Autores principales: Magnani, Giulia, Bonaca, Marc P., Braunwald, Eugene, Dalby, Anthony J., Fox, Keith A. A., Murphy, Sabina A., Nicolau, José Carlos, Oude Ophuis, Ton, Scirica, Benjamin M., Spinar, Jindrich, Theroux, Pierre, Morrow, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392433/
https://www.ncbi.nlm.nih.gov/pubmed/25792124
http://dx.doi.org/10.1161/JAHA.114.001505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392433/
https://www.ncbi.nlm.nih.gov/pubmed/25792124
http://dx.doi.org/10.1161/JAHA.114.001505

Ejemplares similares